Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $37.3 million.

  • Neurocrine Biosciences' Cash from Financing Activities rose 11286.21% to $37.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$38.3 million, marking a year-over-year increase of 9213.07%. This contributed to the annual value of -$38.3 million for FY2025, which is 9213.07% up from last year.
  • Neurocrine Biosciences' Cash from Financing Activities amounted to $37.3 million in Q4 2025, which was up 11286.21% from $45.6 million recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Cash from Financing Activities peaked at $69.9 million during Q1 2024, and registered a low of -$293.0 million during Q2 2024.
  • Over the past 4 years, Neurocrine Biosciences' median Cash from Financing Activities value was $15.1 million (recorded in 2021), while the average stood at -$34.2 million.
  • The largest annual percentage gain for Neurocrine Biosciences' Cash from Financing Activities in the last 5 years was 75243.9% (2024), contrasted with its biggest fall of 1020344.83% (2024).
  • Neurocrine Biosciences' Cash from Financing Activities (Quarter) stood at $15.1 million in 2021, then skyrocketed by 134.44% to $35.4 million in 2023, then crashed by 919.21% to -$290.0 million in 2024, then surged by 112.86% to $37.3 million in 2025.
  • Its Cash from Financing Activities stands at $37.3 million for Q4 2025, versus $45.6 million for Q3 2025 and -$3.3 million for Q2 2025.